Fyrir liggur 6 mánaða uppgjör Norðurþings vegna ársins 2026 og var það kynnt byggðarráði þann 10. september 2026.

Árshlutareikningurinn fyrir tímabilið 1. janúar til 30. júní 2026 er óendurskoðaður og ókannaður.

Árshlutareikningurinn sýnir að fjárhagsstaða Norðurþings byggir á traustum grunni en óhagstætt ytraumhverfi og áhrif lokunar PCC Bakka koma inn af fullum þunga á þessu tímabili og lita reksturinn mjög á tímabilinu.

Halli af rekstri A hluta á tímabilinu nam 404 milljónum króna á móti 232 milljón króna halla á sama tíma í fyrra, en fjárhagsáætlun gerði ráð fyrir 71,1 milljóna króna rekstrarafgangi.
Breyting á lífeyrisskuldbindingu A hluta er 265 milljónir króna á móti 307milljónum króna á síðasta ári og það er þung skuldbinding fyrir sveitarsjóð.
Halli af rekstri samstæðunnar nam 517 milljónum króna á móti 272 milljón króna halla á sama tíma í fyrra, en fjárhagsáætlun gerði ráð fyrir 29 milljóna króna hagnaði.
Veltufé frá rekstri A hluta nemur 26 milljónum króna og veltufé frá rekstri samstæðunnar í heild nemur 72 milljónum króna eða um 2,5% af tekjum.
Handbært fé A hluta er  668 milljónir króna og handbært fé samstæðunnar í heild nemur 1.180 milljónum króna í lok tímabils.
Heildareignir samstæðunnar nema í lok tímabilsins 12.816 milljónum króna og eigið fé samstæðunnar nemur 4.010 milljónum króna.

Attachment

EVANSVILLE, Ind., Sept. 10, 2026 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – Old National Bancorp announced today that its Chairman and Chief Executive Officer Jim Ryan will present at the 2026 Barclays Global Financial Services Conference in New York, NY at 12:00 p.m. ET on Tuesday, September 15, 2026.

Interested parties can access the live webcast of the presentation through the Investor Relations section of the Company’s website at https:/ir.oldnational.com. For those unable to attend the live broadcast, a replay of the presentation will be accessible for 180 days after the presentation date.

ABOUT OLD NATIONAL

Old National Bancorp is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $74 billion of assets and $41 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2026, Points of Light named Old National to “The Civic 50” for the third consecutive year – an honor recognizing the 50 most community-minded companies in the United States – and also named Old National the Financials Sector Leader among nominated banks and financial services organizations.

Investor Relations:
Lynell Durchholz
(812) 464-1366
lynell.durchholz@oldnational.com

Media Relations:
Scott Reinhard 
(612) 716-0304
scott.reinhard@oldnational.com

Männedorf, Switzerland, September 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will participate in the following investor conference next week:

24th Annual Morgan Stanley Healthcare Conference, New York, USA
Date: September 14, 2026
Time: 2:35pm EDT (8:35pm CEST)
Format: Fireside chat with Monica Manotas, CEO, and the Morgan Stanley analyst
Additional participants: Camila Japur, CFO & Martin Braendle, SVP, Corp. Comm. & Investor Relations
Webcast live under the “Investor Relations” tab of Tecan’s website www.tecan.com.
A replay of the webcast will be available after the presentation and will remain available for 120 days.

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2025, Tecan generated sales of CHF 883 million (USD 1,063 million; EUR 939 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
        
        
For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) is pleased to announce that it has completed its previously announced and upsized bought-deal public offering (the “Offering”) of 29,932,200 units of the Company (the “Units”) at a price of C$0.73 per Unit for aggregate gross proceeds to the Company of C$21,850,506, including the full exercise of the over-allotment option.

The Offering was led by Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and ATB Cormark Capital Markets (collectively, the “Underwriters”).

Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.93 until September 10, 2029. The Warrants are expected to commence trading on the TSX Venture Exchange (“TSXV”) under the symbol “RECO.WT.D” in the following week, subject to final TSXV acceptance.

The net proceeds from the Offering will be used for conducting an open-hole horizontal sidetrack and production testing program, targeting the primary reservoir in the Huttenberg formation and/or the secondary reservoir in the Elandshoek formation, and for general corporate purposes and working capital.

The Offering was completed by way of a prospectus supplement, to the Company’s short form base shelf prospectus dated April 13, 2026, with the securities regulatory authorities in each of the provinces of Canada (except Québec). Copies of the base shelf prospectus and any supplement thereto to be filed in connection with the Offering, are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

In connection with the Offering, the Company paid the Underwriters an aggregate cash commission of C$1,282,910.76 and issued to the Underwriters an aggregate of 1,757,412 broker warrants (the “Broker Warrants”). The Underwriters also received an aggregate advisory fee of C$15,000 and an aggregate of 6,000 advisory warrants on the same terms as the Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one Common Share at a price of C$0.73 until September 10, 2029.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About ReconAfrica

ReconAfrica is a Canadian oil and gas company engaged in the exploration of the Damara Fold Belt and Kavango Rift Basin in the Kalahari Desert of northeastern Namibia, southeastern Angola and northwestern Botswana, where the Company holds petroleum licences and access to ~13 million contiguous acres. The Company also operates the Ngulu block in the shallow waters offshore central Gabon covering 1,214 Km2 (equivalent to 54 Gulf of Mexico blocks) which is strategically located near producing oil fields and infrastructure. The Ngulu block includes the Loba oil field discovery and a large inventory of high impact prospects in the pre-salt and post-salt plays. In all aspects of its operations, ReconAfrica is committed to minimal disturbance of habitat in line with international standards and implementing environmental and social best practices in its project areas.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Brian Reinsborough, President & Chief Executive Officer
Mark Friesen, Vice President, Investor Relations & Capital Markets

IR Inquiries Email: investors@reconafrica.com
Media Inquiries Email: media@reconafrica.com
Tel: +1-877-631-1160

Cautionary Note Regarding Forward-Looking Statements:

Certain statements contained in this press release constitute forward-looking information under applicable Canadian, United States and other applicable securities laws, rules and regulations, including, without limitation, statements with respect to the expected use of proceeds from the Offering, the trading of the Warrants on the TSXV and the Company’s commitment to minimal disturbances in line with international best standards and its implementation of environmental and social best practices in all of its project areas. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “potential”, “estimated”, “significant” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on ReconAfrica’s current beliefs or assumptions as to the outcome and timing of such future events. There can be no assurance that such statements will prove to be accurate, as the Company’s actual results and future events could differ materially from those anticipated in these forward-looking statements as a result of the factors discussed in the “Risk Factors” section in the Company’s annual information form (“AIF”) dated April 14, 2026, for the financial period ended December 31, 2025, available under the Company’s profile at www.sedarplus.ca. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to ReconAfrica. The forward-looking information contained in this release is made as of the date hereof and ReconAfrica undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Appointment strengthens feasibility study execution and advances ARR’s pathway to producing separated rare earth oxides in Wyoming

HIGHLIGHTS

  • Dr. Sanja Miskovic appointed Chief Technical Advisor, joining ARR’s technical leadership team effective immediately
  • Will guide flowsheet development, recovery optimisation and process scale-up activities supporting separated rare earth oxide production in Wyoming
  • More than 20 years of minerals processing, beneficiation, extraction and critical materials experience
  • Supports ARR’s strategy to establish a domestic U.S. mine-to-magnet supply chain

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — American Rare Earths Limited (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or “the Company”) is pleased to announce the appointment of Dr. Sanja Miskovic as Chief Technical Advisor, effective immediately.

TECHNICAL LEADERSHIP APPOINTMENT STRENGTHENS ARR’S PATH TO SEPARATED RARE EARTH OXIDES

Dr. Miskovic will focus on process and recovery optimization as part of the feasibility study for the Company’s flagship Halleck Creek Rare Earths Project in Wyoming, USA. In this role, she will guide flowsheet development, beneficiation and hydrometallurgical recovery, and scale up decisions that support the production of separated rare earth oxides at the planned Wyoming processing site.

TWO DECADES OF PROCESS ENGINEERING AND CRITICAL MINERALS EXPERIENCE

Dr. Miskovic is a minerals and process engineering expert with more than 20 years of experience spanning academic and industrial research and development. Her expertise includes the development, design, optimization, and scale up of technologies for mineral beneficiation, chemical extraction, pyrometallurgical and thermal processing, and critical materials recovery.

Her career has covered energy and water efficient mineral liberation and concentration, metal extraction, purification and refining, and the development of high efficiency process equipment and reactor technologies, with projects progressing from laboratory proof of concept through pilot scale validation and industrial implementation.

Dr. Miskovic received her Ph.D. in Minerals Engineering from Virginia Tech in 2011 and holds M.Sc. and B.Sc. degrees from the University of Novi Sad. She serves as Chief Technology Officer of Novex, ARR’s downstream metallization technology partner, and holds an academic appointment at the University of British Columbia’s Norman B. Keevil Institute of Mining Engineering.

ADVANCING THE MINE TO MAGNET STRATEGY

Dr. Miskovic’s appointment reinforces the technical bench advancing Halleck Creek from resource to production and links directly to ARR’s strategy of building a generational U.S. domestic mine to magnet supply chain. Optimizing recovery at the front end of the flowsheet supports the delivery of separated rare earth oxides that feed into metallization, alloying, and permanent magnet production within the United States.

“Sanja brings the technical depth and operating instinct we need as we move Halleck Creek through feasibility and toward construction. Her focus on recovery and process optimization directly supports our objective of producing separated rare earth oxides in Wyoming and feeding those oxides into a domestic metallization and magnet supply chain. Her appointment strengthens an already strong technical team and reflects the continued focus on finding the best talent to advance the Halleck Creek project towards execution.”

– Mark Wall, Chief Executive Officer, American Rare Earths

“Halleck Creek is one of the most important rare earth developments in the United States, and the opportunity to shape process design and recovery decisions during feasibility is a rare one. I look forward to working with the American Rare Earths team to advance a flowsheet that delivers separated rare earth oxides efficiently and reliably, and that supports the broader ambition of a fully integrated U.S. mine to magnet supply chain.”

– Dr. Sanja Miskovic, Chief Technical Officer, Novex LLC

This announcement has been authorized for release by the Board of American Rare Earths Limited.

INVESTOR CONTACT

Investor Relations
Nick Lissolo
nlissolo@americanree.com
www.americanree.com
Stock Information
ASX: ARR
OTCQX: ARRNF
ADR: AMRRY

Media Contact:
Susan Assadi
sassadi@americanree.com
347 977 7125

Additional Investor Relations US Contact:
Beverly Jedynak
Beverly.jedynak@viriathus.com
312 943 1123


ABOUT AMERICAN RARE EARTHS LIMITED

American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is a critical minerals company at the forefront of reshaping the U.S. rare earths industry. Through its wholly owned subsidiary, Wyoming Rare (USA) Inc. (“WRI”), the company is advancing the Halleck Creek Project in Wyoming, a world class rare earth deposit with the potential to secure America’s critical mineral independence for generations. Located on Wyoming State land, the Cowboy State Mine within Halleck Creek offers cost efficient open pit mining methods and benefits from streamlined permitting processes in this mining friendly state.

With plans for onsite mineral processing and separation facilities, Halleck Creek is strategically positioned to reduce U.S. reliance on imports, predominantly from China, while meeting the growing demand for rare earth elements essential to defense, advanced technologies, and economic security. As exploration progresses, the project’s untapped potential on both State and Federal lands further reinforces its significance as a cornerstone of U.S. supply chain security. In addition to its resource potential, American Rare Earths is committed to environmentally responsible mining practices and continues to collaborate with U.S. Government supported R&D programs to develop innovative extraction and processing technologies for rare earth elements. Further information is available at www.americanree.com.

Collaboration with NCI’s Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens

IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration

LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who assumes regulatory sponsorship will support further clinical and non-clinical development of IMNN-001, the Company’s DNA-based IL-12 immunotherapy, under the NCI Experimental Therapeutics (NExT) Program managed by CTEP. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.

Under the agreement, NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens, building on clinical data from the Company’s ongoing ovarian cancer program. IMUNON will retain ownership of its background intellectual property and will retain ownership of new intellectual property solely generated by IMUNON under the collaboration, including the right to use the data generated under the collaboration for the research and development of IMNN-001. For IMUNON, the collaboration provides an opportunity to leverage the NCI resources for generating additional clinical data for IMNN-001 in new indications.

“We believe our CRADA with NCI’s CTEP will explore the broad potential of IMNN-001 and our TheraPlas® platform,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “This partnership allows us to efficiently explore new indications and combinations through the expertise of CTEP and the National Clinical Trials Network (NCTN) utilizing the centralized clinical trial infrastructure funded by NCI, while keeping our team fully focused on advancing our pivotal Phase 3 OVATION 3 study in frontline ovarian cancer as rapidly as possible.”

“The mechanistic rationale for IL-12 as a multipotent immune activator extends well beyond ovarian cancer, and this collaboration gives us a capital-efficient way to initiate additional clinical trials for IMNN-001 across diverse solid tumor types and indications,” said Douglas V. Faller, M.D., Ph.D., Executive Vice President and Chief Medical Officer of IMUNON.

IMNN-001 is currently being evaluated in IMUNON’s pivotal Phase 3 OVATION 3 trial in frontline advanced ovarian cancer, following encouraging results from the completed Phase 2 OVATION 2 study, in which IMNN-001 was associated with a 14.7-month increase in median overall survival compared to chemotherapy alone (45.1 vs. 30.4 months).

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 plus neoadjuvant and adjuvant chemotherapy compared to standard-of-care chemotherapy alone in 112 patients with newly diagnosed advanced ovarian cancer. IMNN-001 is now being evaluated in the Company’s pivotal Phase 3 OVATION 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the U.S.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investors Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

TKM Grupp AS informed the stock exchange on 11 March 2026 of the completion of a transaction pursuant to which the Group’s subsidiary TKM Auto OÜ acquired 100% of the shares in Rohe Auto AS, 100% of the shares in SKO Motors OÜ and 100% of the shares in SKO Motors Kinnisvara OÜ. Rohe Auto AS and SKO Motors OÜ, acquired through the transaction, have been integrated into the Group’s car segment thereby strengthening the Group’s position in the Estonian automotive market. As a result of the transaction, the Group became the largest Škoda dealer in the Baltics.

Considering the corporate structure and business segments of TKM Grupp AS, it has been decided to merge SKO Motors Kinnisvara OÜ, the real estate company acquired as part of the above-mentioned transaction, with TKM Kinnisvara AS, which belongs to the Group’s real estate segment. To this end, a merger will be carried out whereby TKM Kinnisvara AS (as the acquiring company) will merge SKO Motors Kinnisvara OÜ (as the company being acquired) into itself.

Today, the parties signed the merger agreement in connection with the above-mentioned merger. The merger is expected to be registered in the Commercial Register in November 2026.

Raul Puusepp
Chairman of the Board
Phone: +372 731 5000
info@tkmgrupp.ee

RISHON LE ZION, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies for the aerospace, defense, industrial and retail sectors, announced today that it will release financial results for the third quarter of 2026 before the market opens on Monday, November 30, 2026.

Additionally, BOS will host a video conference call on November 30, 2026, at 8:30 a.m. Eastern Time. A question-and-answer session will follow management’s presentation.

To access the video conference meeting, please click on the following link:

https://us06web.zoom.us/j/88403627595?pwd=IvzvcHZooR8CiO7jY4tap56J04OdSQ.1

For those unable to participate in the video conference, a recording of the meeting will be available the next day on the BOS website: www.boscom.com

About BOS

BOS integrates cutting-edge technologies to streamline and enhance supply chain operations for global customers in the aerospace, defense, industrial and retail sectors. The Company operates three specialized divisions:

Supply Chain Division
Distributes and integrates franchised electronic components directly into customer products.

RFID Division
Optimizes customers’ inventory management through state-of-the-art marking and tracking solutions, ensuring real-time visibility and control.

Intelligent Robotics Division
Automates industrial and logistics inventory processes through advanced robotics technologies, improving efficiency and precision.

For more information on BOS Better Online Solutions Ltd., visit www.boscom.com.

Contacts:

Eyal Cohen, CEO
BOS | +972-542525925 | eyalc@boscom.com

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or a few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the effect of the ongoing armed conflict and security conditions in Israel and in the region, the continued availability of financing for working capital purposes and to refinance outstanding indebtedness, the risk that a customer order, including the order described herein, may be delayed, modified, or canceled prior to completion of delivery; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission. BOS undertakes no obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

PRESS RELEASE
Paris, 10 September, 2026

Information on the total number of voting rights
and shares forming the share capital

(Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the French Financial Markets Authority)

Date Issued capital Par value Total number of shares Total number of voting rights
Theoretical* Exercisable**
 

August 31, 2026

 

€ 245,607,624 € 1 245,607,624 276,893,345 272,826,627

*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.
**The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.


About Valeo

As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group’s growth drivers.

Valeo in figures: 20.9 billion euros in sales in 2025 | 100,216 employees, 29 countries, 149 plants, 59 research and development centers, 18 distribution platforms at December 31, 2025.

Valeo is listed on the Paris Stock Exchange.  

Attachment

Transaction in Own Shares

September 09, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 09 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
09/09/2026 895,000 £ 35.4500 £ 34.9700 £ 35.2051 LSE GBP
09/09/2026 125,712 £ 35.1100 £ 34.9800 £ 35.0574 Chi-X (CXE) GBP
09/09/2026 – – – – BATS (BXE) GBP
09/09/2026 500,000 € 41.3700 € 40.8500 € 41.1095 XAMS EUR
09/09/2026 – – – – CBOE DXE EUR
09/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

 

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.